Acorah Software Products - Accounts Production 16.1.300 false true true 30 June 2023 1 July 2022 false 1 July 2023 30 June 2024 30 June 2024 13135667 Mr Hendrik Friedrich Peter Runge Dr. Ulrich Felix Keyser Dr Max Zhu Mr John Mark Yeomans iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13135667 frs-core:Non-currentFinancialInstruments frs-core:BetweenOneFiveYears 2024-06-30 13135667 2023-06-30 13135667 2024-06-30 13135667 2023-07-01 2024-06-30 13135667 frs-core:CurrentFinancialInstruments 2024-06-30 13135667 frs-core:Non-currentFinancialInstruments 2024-06-30 13135667 frs-core:ShareCapital 2024-06-30 13135667 frs-core:RetainedEarningsAccumulatedLosses 2024-06-30 13135667 frs-bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 13135667 frs-bus:FilletedAccounts 2023-07-01 2024-06-30 13135667 frs-bus:SmallEntities 2023-07-01 2024-06-30 13135667 frs-bus:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 13135667 frs-bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 13135667 frs-bus:Director1 2023-07-01 2024-06-30 13135667 frs-bus:Director2 2023-07-01 2024-06-30 13135667 frs-bus:Director3 2023-07-01 2024-06-30 13135667 frs-bus:Director4 2023-07-01 2024-06-30 13135667 frs-countries:EnglandWales 2023-07-01 2024-06-30 13135667 frs-core:Non-currentFinancialInstruments frs-core:BetweenOneFiveYears 2023-06-30 13135667 2022-06-30 13135667 2023-06-30 13135667 2022-07-01 2023-06-30 13135667 frs-core:CurrentFinancialInstruments 2023-06-30 13135667 frs-core:Non-currentFinancialInstruments 2023-06-30 13135667 frs-core:ShareCapital 2023-06-30 13135667 frs-core:RetainedEarningsAccumulatedLosses 2023-06-30
Registered number: 13135667
Cambridge Nucleomics Ltd
Unaudited Financial Statements
For The Year Ended 30 June 2024
Max Accountants Ltd
Ketton Suite
The King Centre
Oakham
Rutland
LE15 7WD
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—5
Page 1
Balance Sheet
Registered number: 13135667
2024 2023
Notes £ £ £ £
CURRENT ASSETS
Debtors 4 25,161 13,049
Cash at bank and in hand 10,387 41,577
35,548 54,626
Creditors: Amounts Falling Due Within One Year 5 (14,491 ) (4,201 )
NET CURRENT ASSETS (LIABILITIES) 21,057 50,425
TOTAL ASSETS LESS CURRENT LIABILITIES 21,057 50,425
Creditors: Amounts Falling Due After More Than One Year 6 (128,362 ) (128,362 )
NET LIABILITIES (107,305 ) (77,937 )
CAPITAL AND RESERVES
Called up share capital 8 5 5
Profit and Loss Account (107,310 ) (77,942 )
SHAREHOLDERS' FUNDS (107,305) (77,937)
Page 1
Page 2
For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Hendrik Friedrich Peter Runge
Director
24 March 2025
The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Cambridge Nucleomics Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13135667 . The registered office is Ketton Suite King Centre, Main Road, Barleythorpe, Oakham, Rutland, LE15 7WD.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern. Therefore the financial statements have been prepared on a going concern basis which assumes the Company will continue in operational existence for the foreseeable future. 
The Company is involved in research and development activities and is working towards achieving a sustainable revenue generating activity. The directors have considered the basis of the financial statements and are satisfied that a combination of business growth and further investment commitments will enable the Company to meet its liabilities as they fall due.
2.3. Turnover
Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
2.4. Cash and Cash Equivalents
Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.
2.5. Financial Instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Basic financial assets
Basic financial assets, which include debtors and bank balances, are measured at transaction price including transaction costs.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, are recognised at transaction price including transaction costs.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities.
2.6. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Page 3
Page 4
2.7. Taxation
Tax is recognised in profit or loss except that a charge is attributable to an item of income and expense recognised as other comphrehensive income or to an item recognised directly in equity is also recognised in other comphrehensive income or directly in equity respectively.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.
2.8. Government Grant
Government grants are recognised in the profit and loss account in an appropriate manner that matches them with the expenditure towards which they are intended to contribute.
Grants for immediate financial support or to cover costs already incurred are recognised immediately in the profit and loss account. Grants towards general activities of the entity over a specific period are recognised in the profit and loss account over that period.
Grants towards fixed assets are recognised over the expected useful lives of the related assets and are treated as deferred income and released to the profit and loss account over the useful life of the asset concerned.
All grants in the profit and loss account are recognised when all conditions for receipt have been complied with.
2.9. Research and Development
In the research phase of an internal project, it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives. 
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only. 
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2023: 2)
2 2
4. Debtors
2024 2023
£ £
Due within one year
Corporation tax recoverable 16,626 12,501
VAT 7,802 548
Other taxes and social security 683 -
Net wages 50 -
25,161 13,049
5. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Trade creditors 7,091 -
Net wages - 951
Accruals and deferred income 7,400 3,250
14,491 4,201
6. Creditors: Amounts Falling Due After More Than One Year
2024 2023
£ £
Other loans 128,362 128,362
Page 4
Page 5
7. Loans
An analysis of the maturity of loans is given below:
2024 2023
£ £
Amounts falling due between one and five years:
Other loans 128,362 128,362
8. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 5 5
Page 5